Last reviewed · How we verify
BHV3241, verdiperstat
BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2).
BHV3241, also known as verdiperstat, is a small molecule inhibitor of the enzyme NADPH oxidase 2 (NOX2). Used for Multiple system atrophy (MSA).
At a glance
| Generic name | BHV3241, verdiperstat |
|---|---|
| Sponsor | Biohaven Pharmaceuticals, Inc. |
| Drug class | NADPH oxidase 2 inhibitor |
| Target | NOX2 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting NOX2, BHV3241 reduces the production of reactive oxygen species (ROS) in microglia, which are a type of immune cell in the brain. This reduction in ROS production is thought to be beneficial in treating neurodegenerative diseases such as multiple system atrophy (MSA).
Approved indications
- Multiple system atrophy (MSA)
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology (PHASE1)
- Study of BHV-3241 in Participants With Multiple System Atrophy (PHASE3)
- Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
- Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BHV3241, verdiperstat CI brief — competitive landscape report
- BHV3241, verdiperstat updates RSS · CI watch RSS
- Biohaven Pharmaceuticals, Inc. portfolio CI